EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab By Ogkologos - October 23, 2025 225 0 Facebook Twitter Google+ Pinterest WhatsApp It adopted a new route for administration along with a new pharmaceutical form Source RELATED ARTICLESMORE FROM AUTHOR ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer MOST POPULAR Study Provides Closer Look at Postmenopausal Bleeding and Endometrial Cancer August 29, 2018 COVID-19: “It could take months to build research up again” July 1, 2020 Efficacy of ICI Combined with Chemotherapy in Patients with Advanced Penile... October 1, 2025 “If there is an under-representation of ethnic minority communities, there will... September 18, 2020 Load more HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Amivantamab Female Representation at the Top of the Oncology Field Has Hit... Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over... Are differences in treatment driving variation in ovarian cancer survival internationally?
